The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia
Here, we are the first to demonstrate the ability of CBDV to ameliorate cognitive and social deficits in the scPCP rat model of relevance for schizophrenia, suggesting further research is justified into the potential therapeutic benefits of CBDV in patients.
Authors
- Ben Grayson (ORCID: https://orcid.org/0000-0001-6843-898X)
- Jennifer Fletcher (ORCID: https://orcid.org/0000-0003-0949-4484)
- Joanna Caroline Neill (ORCID: https://orcid.org/0000-0002-2717-9739)
- Jackie Cilia (ORCID: https://orcid.org/0000-0003-1750-0629)
- Michael Harte (ORCID: https://orcid.org/0000-0002-4702-4785)
- Marie Woolley-Roberts
- Giovanni Podda (ORCID: https://orcid.org/0000-0002-9158-371X)
Institutions
- Manchester Academic Health Science Centre (GB)
- Sittingbourne Memorial Hospital (GB)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1177/02698811251381246
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00